Literature DB >> 14676659

Paradoxical cytoskeleton and microparticle formation changes in monocytes and polymorphonuclear leukocytes in severe systemic inflammatory response syndrome patients.

Yuka Itakura Sumi1, Hiroshi Ogura, Hiroshi Tanaka, Taichin Koh, Kieko Fujita, Satoshi Fujimi, Yasushi Nakamori, Takeshi Shimazu, Hisashi Sugimoto.   

Abstract

BACKGROUND: Circulating monocytes and polymorphonuclear leukocytes (PMNLs) are considered as central regulators controlling systemic inflammatory response after severe insults. Recently, activated monocytes and PMNLs have been reported to produce microparticles (MPs) in vitro. The objective of this study was to evaluate production of MPs and changes of cytoskeleton in monocytes from severe systemic inflammatory response syndrome (SIRS) patients, and to compare them with those in PMNLs.
METHODS: Twenty severe SIRS patients (SIRS criteria and serum C-reactive protein > 10 mg/dL) and 15 healthy volunteers were included. MP formation and F-actin content in monocytes and PMNLs were measured by flow cytometry in the presence or absence of lipopolysaccharide or formylmethionyl-leucyl-phenylalanine (FMLP). The membrane expression of human leukocyte antigen-DR and CD64 in monocytes and O2- production in PMNLs were also measured by flow cytometry.
RESULTS: In severe SIRS patients, MP formation with and without lipopolysaccharide in monocytes significantly decreased in comparison with those in normal controls (p < 0.05), whereas those with and without FMLP in PMNLs increased (p < 0.05). F-actin content with and without FMLP in monocytes also significantly decreased in patients (p < 0.05), whereas those in PMNLs increased as compared with normal controls (p < 0.05). The expression of human leukocyte antigen-DR in monocytes significantly decreased in patients (p < 0.05), which indicated monocyte modulation. The O2- production in PMNLs increased in patients (p < 0.05), which showed PMNL activation.
CONCLUSION: The changes of MP formation and cytoskeleton in circulating monocytes and PMNLs were paradoxically different in severe SIRS patients.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14676659     DOI: 10.1097/01.TA.0000096663.21402.5C

Source DB:  PubMed          Journal:  J Trauma        ISSN: 0022-5282


  6 in total

1.  Downregulation of Microparticle Release and Pro-Inflammatory Properties of Activated Human Polymorphonuclear Neutrophils by LMW Fucoidan.

Authors:  João Alfredo Moraes; Ana Clara Frony; Pedro Barcellos-de-Souza; Marcel Menezes da Cunha; Thayanne Brasil Barbosa Calcia; Claudia Farias Benjamim; Catherine Boisson-Vidal; Christina Barja-Fidalgo
Journal:  J Innate Immun       Date:  2018-12-17       Impact factor: 7.349

Review 2.  Neutrophil derived microvesicles: emerging role of a key mediator to the immune response.

Authors:  Bobby L Johnson; Josh W Kuethe; Charles C Caldwell
Journal:  Endocr Metab Immune Disord Drug Targets       Date:  2014       Impact factor: 2.895

3.  Preliminary study of microparticle coagulation properties in septic patients with disseminated intravascular coagulation.

Authors:  Shishuai Meng; Kai Kang; Dongsheng Fei; Songlin Yang; Quankuan Gu; ShangHa Pan; Mingyan Zhao
Journal:  J Int Med Res       Date:  2021-05       Impact factor: 1.671

Review 4.  Bench-to-bedside review: circulating microparticles--a new player in sepsis?

Authors:  Ferhat Meziani; Xavier Delabranche; Pierre Asfar; Florence Toti
Journal:  Crit Care       Date:  2010-10-20       Impact factor: 9.097

5.  Changes in monoclonal HLA-DR antigen expression in acute organophosphorus pesticide-poisoned patients.

Authors:  Chenyun Xia; Mi Wang; Qi Liang; Ling'an Yun; Housheng Kang; Lei Fan; Dongsheng Wang; Guoyuan Zhang
Journal:  Exp Ther Med       Date:  2013-10-22       Impact factor: 2.447

Review 6.  Extracellular vesicle profiling and their use as potential disease specific biomarker.

Authors:  Henrike Julich; Arnulf Willms; Veronika Lukacs-Kornek; Miroslaw Kornek
Journal:  Front Immunol       Date:  2014-09-01       Impact factor: 7.561

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.